In addition to the Orphan Products Grants Program that the Office of Orphan Products Development (OOPD) currently administers, a new grant program was established this year by the Accelerating Access to Critical Therapies for Amyotrophic Lateral Sclerosis Act (ACT for ALS) named the FDA Rare Neurodegenerative Disease Grant Program. This new program will be administered by OOPD to promote medical product development for rare neurodegenerative diseases such as ALS.
More information about the programme : Rare Neurodegenerative Disease Grant Program | FDA
To plan for future RFAs for this new program, FDA recently announced a call for comments on current funding needs in the rare neurodegenerative disease space that could be supported by grants from the Office of Orphan Products Development. If you have interest in this space, please consider providing comments to the open docket. The comment period closes on November 28, 2022.